Q BioMed Inc CEO Denis Corin caught up with Proactive to share a recap of the biotech group's 2021 achievements, including progress with its drug Strontium-89, including its financial performance, with 2021 year-over-year revenue increasing by 600%.
What's more, Corin expanded on progress the group expects from its the remainder of its pipeline in 2022 as well as its expected uplist to the Nasdaq.